Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female subjects 30-65 years
- Body Mass Index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
Exclusion Criteria:
- History of any clinically significant disease or disorder
- History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- Previous history of frequent pre-syncope or syncope
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AZD3241
AZD3241 Tablets
|
Oral Tablet, Repeated Administration
|
|
Experimental: Placebo
Placebo Tablets
|
Oral Tablet.
Repeated Administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety variables (adverse events, vital signs, ECG, safety lab)
Time Frame: Assessments performed at frequent timepoints during a 4-8 week period
|
Assessments performed at frequent timepoints during a 4-8 week period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To characterize the pharmacokinetics of AZD3241 in plasma
Time Frame: Frequent sampling occasions during some study days for a 4-8 weeks period
|
Frequent sampling occasions during some study days for a 4-8 weeks period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Rolf Karlsten, MD, Medical Science Director AstraZeneca R&D Södertälje.
- Principal Investigator: Wolfgang Kuhn, MD, PhD, Quintiles AB Phase I Unit, Uppsala, Sweden
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- D0490C00002
- EudraCT No 2007-003145-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.